語系:
繁體中文
English
說明(常見問題)
圖資館首頁
登入
回首頁
到查詢結果
[ author_sort:"ganai, shabir ahmad." ]
切換:
標籤
|
MARC模式
|
ISBD
Histone deacetylase inhibitors in co...
~
Ganai, Shabir Ahmad.
Histone deacetylase inhibitors in combinatorial anticancer therapy
紀錄類型:
書目-電子資源 : Monograph/item
正題名/作者:
Histone deacetylase inhibitors in combinatorial anticancer therapyby Shabir Ahmad Ganai.
作者:
Ganai, Shabir Ahmad.
出版者:
Singapore :Springer Singapore :2020.
面頁冊數:
xvii, 258 p. :ill. (some col.), digital ;24 cm.
Contained By:
Springer Nature eBook
標題:
Histone deacetylaseInhibitors.
電子資源:
https://doi.org/10.1007/978-981-15-8179-3
ISBN:
9789811581793$q(electronic bk.)
Histone deacetylase inhibitors in combinatorial anticancer therapy
Ganai, Shabir Ahmad.
Histone deacetylase inhibitors in combinatorial anticancer therapy
[electronic resource] /by Shabir Ahmad Ganai. - Singapore :Springer Singapore :2020. - xvii, 258 p. :ill. (some col.), digital ;24 cm.
Chapter 1_Epigenetic modifying enzymes. -Chapter 2_Epigenetic modifying enzymes implicated in cancer. -Chapter 3_Classification of histone deacetylases (HDACs) -Chapter 4_Implications of 18 HDAC isoforms in therapeutically monotonous cancers. -Chapter 5_Possible Mechanisms of HDACs in Cancer development -- Chapter 6_Different strategies employed for circumventing cancer resistance (chemo and radio) and mitigating toxicity. -Chapter 7_Limitations of conventional therapeutic regimens in treating cancer. -Chapter 8_Overview of epidrugs with special emphasis on HDAC inhibitors (HDACi) -- Chapter 9_HDAC inhibitors as promising epidrugs for treating cancer. -Chapter 10_ HDAC inhibitors in anticancer monotherapy. -Chapter 11_Distinct groups of histone deacetylase inhibitors (HDACi) based on the structural distinction, HDACs targeted. -Chapter 12_Limited efficacy of HDAC inhibitor-based monotherapy. -Chapter 13_Resistance mechanisms generated by cancer cells against HDACi based monotherapy. -Chapter 14_ Toxicity issue of HDAC inhibitor based monotherapy. -Chapter 15_Combinatorial therapeutic strategies of HDACi. -Chapter 16_Designing Selective HDACi using computational and medicinal chemistry approach. -Chapter 17. Current therapeutic challenges and future directions.
ISBN: 9789811581793$q(electronic bk.)
Standard No.: 10.1007/978-981-15-8179-3doiSubjects--Topical Terms:
878079
Histone deacetylase
--Inhibitors.
LC Class. No.: QP552.H5
Dewey Class. No.: 572.66
Histone deacetylase inhibitors in combinatorial anticancer therapy
LDR
:02274nmm a2200313 a 4500
001
589275
003
DE-He213
005
20210224155503.0
006
m d
007
cr nn 008maaau
008
210601s2020 si s 0 eng d
020
$a
9789811581793$q(electronic bk.)
020
$a
9789811581786$q(paper)
024
7
$a
10.1007/978-981-15-8179-3
$2
doi
035
$a
978-981-15-8179-3
040
$a
GP
$c
GP
041
0
$a
eng
050
4
$a
QP552.H5
072
7
$a
MJCL
$2
bicssc
072
7
$a
MED062000
$2
bisacsh
072
7
$a
MJCL
$2
thema
082
0 4
$a
572.66
$2
23
090
$a
QP552.H5
$b
G195 2020
100
1
$a
Ganai, Shabir Ahmad.
$3
878078
245
1 0
$a
Histone deacetylase inhibitors in combinatorial anticancer therapy
$h
[electronic resource] /
$c
by Shabir Ahmad Ganai.
260
$a
Singapore :
$b
Springer Singapore :
$b
Imprint: Springer,
$c
2020.
300
$a
xvii, 258 p. :
$b
ill. (some col.), digital ;
$c
24 cm.
505
0
$a
Chapter 1_Epigenetic modifying enzymes. -Chapter 2_Epigenetic modifying enzymes implicated in cancer. -Chapter 3_Classification of histone deacetylases (HDACs) -Chapter 4_Implications of 18 HDAC isoforms in therapeutically monotonous cancers. -Chapter 5_Possible Mechanisms of HDACs in Cancer development -- Chapter 6_Different strategies employed for circumventing cancer resistance (chemo and radio) and mitigating toxicity. -Chapter 7_Limitations of conventional therapeutic regimens in treating cancer. -Chapter 8_Overview of epidrugs with special emphasis on HDAC inhibitors (HDACi) -- Chapter 9_HDAC inhibitors as promising epidrugs for treating cancer. -Chapter 10_ HDAC inhibitors in anticancer monotherapy. -Chapter 11_Distinct groups of histone deacetylase inhibitors (HDACi) based on the structural distinction, HDACs targeted. -Chapter 12_Limited efficacy of HDAC inhibitor-based monotherapy. -Chapter 13_Resistance mechanisms generated by cancer cells against HDACi based monotherapy. -Chapter 14_ Toxicity issue of HDAC inhibitor based monotherapy. -Chapter 15_Combinatorial therapeutic strategies of HDACi. -Chapter 16_Designing Selective HDACi using computational and medicinal chemistry approach. -Chapter 17. Current therapeutic challenges and future directions.
650
0
$a
Histone deacetylase
$x
Inhibitors.
$3
878079
650
0
$a
Cancer
$x
Treatment.
$3
252269
650
0
$a
Cancer
$x
Research.
$3
341951
650
0
$a
Gene expression.
$3
188888
650
0
$a
Medical genetics.
$3
194842
650
0
$a
Nucleic acids.
$3
194925
650
1 4
$a
Cancer Research.
$3
273660
650
2 4
$a
Gene Expression.
$3
220379
650
2 4
$a
Gene Function.
$3
456568
650
2 4
$a
Nucleic Acid Chemistry.
$3
376665
710
2
$a
SpringerLink (Online service)
$3
273601
773
0
$t
Springer Nature eBook
856
4 0
$u
https://doi.org/10.1007/978-981-15-8179-3
950
$a
Biomedical and Life Sciences (SpringerNature-11642)
筆 0 讀者評論
全部
電子館藏
館藏
1 筆 • 頁數 1 •
1
條碼號
館藏地
館藏流通類別
資料類型
索書號
使用類型
借閱狀態
預約狀態
備註欄
附件
000000191710
電子館藏
1圖書
電子書
EB QP552.H5 G195 2020 2020
一般使用(Normal)
在架
0
1 筆 • 頁數 1 •
1
多媒體
多媒體檔案
https://doi.org/10.1007/978-981-15-8179-3
評論
新增評論
分享你的心得
Export
取書館別
處理中
...
變更密碼
登入